Journal article
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 – final results of the REV1TAL study
J Lubel, S Strasser, KA Stuart, G Dore, A Thompson, S Pianko, S Bollipo, JL Mitchell, V Fragomeli, T Jones, S Chivers, P Gow, D Iser, M Levy, E Tse, A Gazzola, W Cheng, S Nazareth, S Galhenage, A Wade Show all
Antiviral Therapy | INT MEDICAL PRESS LTD | Published : 2017
DOI: 10.3851/IMP3168
Abstract
Background: Limited data exist on the outcomes of ritonavir-boosted paritaprevir with ombitasvir and dasabuvir (PrOD) ± ribavirin in a real-world setting. The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pretreatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment. Methods: 451 patients with hepatitis C genotype 1 treated in 20 centres across Australia were included. Baseline demographic, clinical and laboratory information, on-treatment biochemical, virological and haematological indices and details on serious adverse events were..
View full abstractGrants
Funding Acknowledgements
AbbVie provided drug for patients included in the Compassionate Program and provided funding for the research through an unrestricted grant administered by the Gastroenterological Society of Australia. AbbVie was not involved in the data collection related to this publication. Upon study completion, AbbVie was provided a copy of the publication for the purposes of performing an accuracy review and as a part of routine safety monitoring of patients treated with Viekira Pak (Viekirax)/Exviera.